Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB)

Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB), also operating as Cenra API Solutions (CAS), is a prominent Taiwan-based manufacturer specializing in the research, development, and production of high-value Active Pharmaceutical Ingredients (APIs). Founded in 1964, the company utilizes advanced biotechnology, fermentation, and chemical synthesis platforms to serve global markets, with a strong regulatory track record including approvals from the U.S. FDA, EMA, Japan's PMDA, and Taiwan's TFDA. CCSB provides end-to-end services ranging from early-stage development to commercial-scale manufacturing. Their product portfolio covers various therapeutic areas, including oncology, immunosuppressants, cardiovascular drugs, and antifungal agents. In March 2026, the company announced a strategic joint venture with BioDuro, a global CRDMO, to further enhance its manufacturing capabilities and global supply chain resilience.